C. Baker

发表

Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab

N. Tunariu, Juanita Lopez, U. Banerji, 2020, Journal for ImmunoTherapy of Cancer.

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

Robert Brown, N. Tunariu, C. Yap, 2022, Journal for ImmunoTherapy of Cancer.

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

S. Pettitt, C. Lord, V. Serra, 2021, Cancer discovery.

B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.

C. Drake, N. Tunariu, M. Shen, 2022, European urology.

Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation - a Single Unit Experience.

N. Tunariu, Juanita Lopez, U. Banerji, 2021, Cancer treatment and research communications.

HER-3 Expression and MEK Activation in Non-small Cell Lung Cancer

Juanita Lopez, U. Banerji, B. Gurel, 2020 .

HER3 expression and MEK activation in non-small-cell lung carcinoma

Juanita Lopez, U. Banerji, J. D. de Bono, 2021, Lung cancer management.

A prognostic index for operable, node-negative breast cancer

D. Cameron, C. Purdie, H. Stewart, 2004, British Journal of Cancer.

P4-09-18: Australian Decision Impact Study: The Impact of Oncotype DX Recurrence Score (RS) on Adjuvant Treatment Decisions in Hormone Receptor Positive (HR+), Node Negative (N0) and Node Positive (N+) Early Stage Breast Cancer (ESBC) in the Multidisciplinary Clinic (MDC).

D. Speakman, B. Mann, C. Baker, 2011 .